吉非替尼对比培美曲塞二线治疗晚期非小细胞肺癌的临床研究

目的:探讨吉非替尼和培美曲塞单药二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效有无差别。方法:回顾性分析2009年2月至2011年10月浙江医院呼吸科一线化疗失败后行吉非替尼或培美曲塞二线治疗的晚期NSCLC患者64例,其中吉非替尼组33例,培美曲塞组31例。评价两组患者疾病进展时间及生存期有无差别。结果:吉非替尼组与培美曲塞组相比无疾病进展生存时间(progressionfree survival,PFS)差别无统计学意义(HR=1.21,95%CI:0.68～2.16,χ2=0.41,P=0.52);培美曲塞组总生存期明显长于吉非替尼组(HR=1.99,95%CI:1.04～3.85,χ=4.30,P=0.04);两组患者的毒副反应差别无统计学意义(P>0.05)。结论:对一线化疗失败的晚期NSCLC,吉非替尼与培美曲塞在延长患者PFS方面无差别,但在总生存时间(overal surviv-al,OS)方面培美曲塞组明显好于吉非替尼组,两组患者毒副反应无差别,都可耐受。

Comparison of gefitinib and pemetrexed in treatment of advanced non-small cell lung cancer patients who have failed to first-line chemotherapy

AIM:To evaluate the clinical difference between gefitinib and pemetrexed in treatment of advanced non-small cell lung cancer(NSCLC) patients who have failed to first-line chemotherapy.METHODS: From Feb 2009 to Oct 2011,64 patients with NSCLC who received gefitinib or pemetrexed for second line chemotherapy were analysised retrospectively.The progression survival time and overall survival time were evaluated. RESULTS:There was no statistics difference between the gefitinib and pemetrexed group for progression free survival time(HR=1.21,95%CI:0.68-2.16,χ2=0.41,P=0.52).But the overall survival time for patients received pemetrexed was much longer than that patients received gefinitib(HR=1.99 95%CI:1.04-3.85,χ2=4.30,P=0.04).No statistical difference between the two group in side effect(P>0.05). CONCLUSION: For patients with advanced NSCLC who have failed to first-line chemotherapy,the overall survival time was longer for patients received pemetrexed but not for progression free time in the second line chemotherapy compared with treatment of pemetrexed.The side effect was acceptable and no statistical difference between the two groups was observed.